消息

Revenue composition: inter‑dealer broking (IDB) contributed 623.3 million CHF, retail investors 22.9 million CHF, and joint‑venture income accounted for 646.2 million CHF. The Swiss franc’s appreciation against the US dollar and Japanese yen reduced reported revenue in CHF relative to constant exchange rates, yet the company maintained steady growt...

全文

CFT.SW reported a 10.4 % rise in consolidated revenue at constant exchange rates for the first half of 2026, compared with a 2.2 % increase at current rates. The growth was driven by geopolitical tensions in the Middle East during Q1, while Q2 saw a 3.6 % rise at constant rates and a –1.1 % decline at current rates. Total revenue for the six months...

全文

Oculis' financial position remains strong, with a cash balance providing a runway into 2029. The company's pipeline has shown promising results, with ongoing clinical trials expected to provide further insights into the potential of its product candidates.

全文

The company's pipeline includes Privosegtor for neuroprotection in optic neuritis and potential applications in other neuro‑ophthalmic and neurological indications. Licaminlimab is being developed as a precision medicine treatment for dry eye disease with a genotype‑based approach.

全文

Key upcoming events include medical conferences such as the Asia‑Pacific Vitreo‑Retina Society (APVRS) Congress and the EURETINA 26th Annual Congress, and investor conferences including the Stifel Biotech Summer Summit and the Leerink Biopharma Summit.

全文

The PREDICT‑1 genotype‑based registrational trial of Licaminlimab in dry eye disease (DED) continues with enrollment progressing as planned, and all sites activated, exceeding 45 % patient randomization. The FDA's pre‑IND feedback also supports the proposed clinical development strategy for Privosegtor in optic neuritis.

全文

Oculis Holdings AG (Nasdaq: OCS) reported positive progress in its neuro‑ophthalmology pipeline, with key highlights including the PIONEER program for Privosegtor as a lead late‑stage asset. The FDA has provided pre‑IND feedback supporting the proposed clinical development strategy and regulatory pathway for Privosegtor in acute multiple sclerosis...

全文

Adient (ADNT) has an average rating of overweight and mean price target of $27.45, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 20.01,...

全文

Adient (ADNT) has an average rating of overweight and mean price target of $28.27, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

全文

Investors can track changes in earnings estimate revisions for Adient and other stocks using tools like the Zacks Rank. As of now, the current consensus EPS estimate is $0.73 on $3.63 billion in revenues for the coming quarter and $2.13 on $14.8 billion in revenues for the current fiscal year. The outlook for the industry can also impact the stock'...

全文